jump to navigation

Patients line up for DCA drug trial September 27, 2007

Posted by Dreamhealer in Research.
Tags: ,

DCAMore than 100 people with lung, breast, colon, liver and other cancers flooded the University of Alberta phone lines Wednesday morning, hoping to be part of the first clinical trial to give cancer patients an inexpensive drug that shrank tumours in rats.

But the investigative team of doctors and nurses that will be testing DCA, or dichloroacetate, on patients are only accepting those with malignant brain tumours including multi-forming glioblastoma, commonly called “the terminator” because of its deadliness and resistance to traditional treatments.

In fact, Health Canada approved a phase 2

trial with these patients instead of phase 1 because the patients don’t have time to slowly increase drug dosages of DCA. About half of glioblastoma patients die within one year, even after surgery, chemotherapy and radiation.

“These patients would not survive the duration of the trial if we were to start with very low dosages,” said Dr. Evangelos Michelakis, whose promising research sparked interest across the world early this year. For his clinical trial, he is looking for local newly diagnosed brain cancer patients, and those for whom regular treatments haven’t worked.

Those who are at the end stage of their disease — who are bedridden and need 24-hour care — aren’t eligible to join the trial.

“The important thing is if these patients live better and longer,” Michelakis said of his goal. “Even if someone is stable for six months, that’s a win because usually people deteriorate week by week and month by month.”

Michelakis and his co-investigator in the clinical trial, Dr. Kenn Petruk, head of neurosurgery for Edmonton’s Capital Health Authority, said they will be able to tell if DCA is affecting the cancer cells within one month to six weeks after they start treatment. Using a PET scan — a positron emission tomography machine that Capital Health only secured in March — they will be studying if DCA reduces the amount of glucose metabolized by cancer cells. Cancer cells love sugar.

If they can change the metabolism rate of cancer cells, the researchers hope the tumour will stop growing and might actually shrink, improving quality of life.

Such shrinkage wouldn’t be detectable until six months into the trial. Michelakis said he will release data as the trial progresses. He is also working with Health Canada to see if people from across Canada might be able to participate, though he only needs 50 patients to complete the trial and can’t pay for the medical costs of people from outside Alberta.

“Whether this would be a miracle drug, of course it’s premature to say that. It might not work in human beings.”

Michelakis said the real miracle is that a clinical trial is proceeding without support from the pharmaceutical industry. It usually takes millions of dollars and three years to take a drug to trial. Because DCA has already been shown to be safe in humans with heart disease and metabolic disorders, and because people across the world donated $800,000 to the cause, Michelakis was able to push his idea forward within eight months.

Read More ......


1. joshjoshn - December 16, 2008

Here you can find observation data gathered by Canadian Clinic – Medicor Cancer
Centres durning DCA therapy:
and here are 4 cases treated with DCA:

here’s an lymphoma remission story using DCA B1 vitamine protocol:
and here are other remissions:


for more info on alternative therapies and dca see forums.cancer.vc and for additional info see puredca.com and cancer.vc

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: